A prospective immunogenicity trial of measles and rubella vaccines was conducted in Oman. Children received measles vaccine at age 9 months and measles-rubella vaccine at age 15 months. Serum specimens were tested for measles-specific IgG and rubella-specific IgG. Of 1025 eligible infants, 881 (86.0%) returned for all five visits and had adequate serum samples for testing. Seroconversion to measles after vaccination at 9 months was 98.1%. At 15 months, 47 (5.3%) of the 881 children were seronegative for measles; of these, 44 (93.6%) seroconverted. At 16 months, 99% of the children seronegative at age 9 months seroconverted after receiving two doses of measles vaccine. At age 15 months, 684 (77.6%) children were seronegative for rubella. Of these, 676 (98.8%) seroconverted by age 16 months. One dose of measles vaccine at age 9 months was highly immunogenic. One dose of measles-rubella vaccine at age 15 months closed the remaining measles immunogenicity gap and resulted in a high rate of rubella seroconversion.
periodic large-scale outbreaks could be expected to occur unless the national immunization program could implement additional measles control strategies.
Oman experienced a rubella outbreak in 1987-1988 with 257 reported rubella cases. This epidemic resulted in 34 infants with congenital rubella syndrome (CRS) [2] . Concern about rubella led the Ministry of Health to conduct additional studies and to consider the possible introduction of rubella vaccine. A large-scale serosurvey among women of childbearing age in December 1988 to January 1989, following the rubella epidemic, indicated gaps in rubella immunity that
The study protocols for phase I and phase II of this clinical trial were approved by the National Maternal Child Health Committee, Ministry of Health, Oman; the Institutional Review Board, Centers for Disease Control and Prevention, Atlanta; and the Secretariat Committee for Research Involving Human Subjects, World Health Organization, Geneva. Witnessed oral parental consent was obtained for each study subject; consent was obtained separately for phase I and phase II of the study. could lead to further cases of CRS [3] . Overall, 91% of 481 serum specimens from women of childbearing age were seropositive for rubella IgG. Seropositivity rates did not show much variation by age group (15-44 years), but there were significant differences by region, with Muscat having 95.6%, Ad Dakhilyah 92.2%, South Al Batinah 92.3%, Adh Dhahirah 89.7%, North Al Batinah 88.7%, Ash Sharqiyah 85.0%, and Dhofar 70.0%. The antenatal serosurvey also measured measles IgG antibody, and overall, 96.7% of 481 sera tested were seropositive, ranging by region from 90% in Dhofar to 97% in Muscat. None of the women enrolled in the antenatal serosurvey would have received either measles vaccine or rubella vaccine; thus, their antibody levels represent the effects of natural infection with the wild viruses.
In planning the present clinical trial, the Ministry of Health of Oman was contemplating the potential benefits of adding a single dose of measles-rubella (MR) vaccine to the immunization schedule at 15 months of age. Therefore, this trial was carried out to assess the immunogenicity of a schedule with two doses of measles vaccine and one dose of rubella vaccine. The study aimed to provide background data that would justify recommendations for a change in the national immunization schedule.
METHODS

Study design.
The overall design of this clinical trial has been described [4] . The study was conducted between August 1992 and April 1993 at the pediatric outpatient clinics of health facilities in four areas of Oman: Royal Hospital in Muscat, the capital city, and the national tertiary referral center; Seeb Health Center in a suburb of Muscat; Ibra Regional Hospital, the sole hospital in North Ash Sharqiyah Region; and Nizwa Regional Hospital, the sole hospital for Ad Dakhilyah Region. During phase I of the study, infants presenting at age 9 months received a single dose of measles vaccine and were followed 7 and 30 days later. For phase II of the study, children from phase I returned at age 15 months for a dose of MR vaccine and were followed 30 days later.
Study population. Parents were informed about the vaccine trial when they brought their infants for the 7-month routine well-baby checkup. At the 9-month visit for measles vaccination, parents were again informed about the vaccine trial and formally asked whether they wished to have their child participate. All healthy 9-month-old infants at each study site were eligible for phase I. Children were ineligible for participation if they had medical conditions requiring hospitalization, were immunocompromised, had an immunodeficient family member, or resided 11 h by car from the study site. For phase II, the 1000 children who completed phase I and returned for a visit at age 15 months were eligible.
Ethical approval and informed consent. Prior to participating in the study, each child's parent was informed about the purpose, methods, possible risks and benefits of the study, and the voluntary nature of participation. A standard questionnaire concerning demographic characteristics, medical and vaccination histories, and socioeconomic status was administered to each child's parent at the start of the study. At each visit, study children were first seen by a study physician who completed a physical examination and asked specific questions about respiratory infection, fever, and any other illnesses since the last visit.
Rash illness surveillance during the study. In 1991, Oman implemented a national communicable diseases surveillance system, which included clinical case definitions for measles and rubella and required immediate reporting of these diseases from all regions of the country [5] . Outbreak investigation guidelines called for collection of blood specimens from several case patients in each outbreak to confirm the diagnosis. Limited confirmatory measles and rubella IgM testing was available within the country.
Vaccines. Monovalent live attenuated measles virus vaccine formulated to contain 4.0 log 10 median TCID 50 of Schwarz measles virus strain was donated for this study by the manufacturer (SmithKline Beecham; lot no. M155L12A). Bivalent live attenuated MR vaccine formulated to contain 4.0 log 10 TCID 50 of Schwarz strain measles virus and 4.2 log 10 TCID 50 of RA27/3 strain of rubella virus was donated by the manufacturer (SmithKline Beecham; lot number MR10A43). Both vaccines were provided in single-dose vials. Each vial of lyophilized vaccine was reconstituted with diluent provided by the manufacturer to prepare one 0.5-mL dose of vaccine, which was administered intramuscularly according to standard practice in Oman [6] . Both types of vaccine were shipped on dry ice from the manufacturer in Rixensart, Belgium, directly to Muscat, Oman. Vaccines were stored at Ϫ20ЊC at the Central Cold Store in Muscat. Periodically, vaccine shipments were sent to the study sites, with strict attention paid to the cold chain. The temperature of all vaccine storage areas was monitored twice daily; no cold chain breaks were recorded. The potency of the measles and rubella vaccines was assessed according to standard procedures at two laboratories [7] . The laboratories determined the titer of each virus and conducted a standard test of thermal stability after 7 days at 37ЊC. Results are reported as the means of the values from the two laboratories. The monovalent measles vaccine potency was 4.1 log 10 TCID 50 of measles virus per dose. The bivalent MR vaccine potency was 3.9 log 10 TCID 50 of measles virus and 3.6 log 10 TCID 50 of rubella virus per dose. Both the monovalent and bivalent vaccines passed the thermal stability test.
Collection and processing of blood specimens. In phase I of the study, 2-to 4-mL blood samples were obtained from each study child by venipuncture at 9 months of age prior to administration of measles vaccine and 7 and 30 days after immunization. In phase II of the study, 2-to 4-mL blood samples were obtained from each study child by venipuncture at 15 months of age prior to administration of MR vaccine and 30 days after immunization. Each study site laboratory processed study blood specimens daily: Sera were separated by centrifugation, labeled with a numeric code, and stored frozen at Ϫ20ЊC. At the end of the field portion of the study, specimens were shipped on dry ice to the Centers for Disease Control and Prevention (CDC; Atlanta) for measles testing. Aliquots of the 15-and 16-month serum specimens were shipped on dry ice from CDC to the Central Public Health Laboratory (London) for rubella IgG antibody testing. All serologic tests were conducted blinded.
Laboratory tests. Measles-specific IgG antibodies were assayed by use of a previously described EIA [8] . Measles IgG antibody test results were reported as positive, negative, or indeterminate. Detection of antibodies to measles nucleoprotein is a reliable surrogate for an immune response to measles infection. The indirect EIA gives predictive values for both positive and negative tests in excess of 90%, with sensitivity 190% and specificity 198% [9] . All negative and a comparable number of randomly sampled known positive specimens were retested. Rubella-specific IgG antibodies were quantitatively screened by using the Bioelisa rubella IgG ELISA test kit (Biokit) according to the manufacturer's instructions. Nonimmune was defined as a rubella IgG concentration !10 IU/mL; immune was defined as a concentration of у10 IU/mL. Seroconversion after vaccination was defined as a change from IgG antibody negative to positive over a given time period.
Statistical analyses. Seroprevalence for measles antibodies was calculated overall and by study site for the cohort of children with sera at all five visits (i.e., at 9 months, 9 months plus 7 days, 10 months, 15 months, and 16 months of age). Seroconversion rates to measles after the first dose were calculated by study site for infants seronegative at the 9-month visit. Measles seroconversion following two doses of vaccine was calculated at age 16 months for those who were seronegative at age 15 months. Rubella antibody seroprevalence was calculated overall and by study site at age 15 and 16 months. Seroconversion rates for rubella were calculated overall and by study site for children seronegative for rubella-specific IgG at the 15-month visit. Indeterminate results were excluded from all seroconversion analyses.
Statistical analyses were done with SAS software (v. 6.12; SAS). Differences in seroprevalence rates between sites and in proportions between groups were assessed by use of MantelHaenszel x 2 tests. Fisher's exact test (2-tailed) was used when the expected number in a cell was !5. Statistical significance was defined as . P ! .05
RESULTS
In total, 1025 infants were enrolled in the vaccine trial between August 1992 and February 1993. Of these, 881 (86.0%) were seen at 9 months, 9 months plus 7 days, 10 months, 15 months, and 16 months and had adequate serum samples at all visits. The median age (range) for the children at each visit was 9 months (8.3-11.7) at the first visit, 9.3 months (8.5-11.9) at the second visit, 10.1 months (9.3-12.7) at the third visit, 15.4 months (14.4-19. 3) at the fourth visit, and 16.5 months (15.4-20.4) at the fifth visit. Ibra and Nizwa hospitals each had 254 children with complete data for all visits, while Royal had 198 and Seeb had 175.
Demographic and clinical characteristics of the 881 infants at the first visit are shown in table 1 by study site. As expected, socioeconomic status differed between the four study sites. The educational status of both mothers and fathers was highest at Royal Hospital and lowest at Ibra Regional Hospital, and families from Royal Hospital were more likely than families from the other sites to have cars. Ibra Hospital had the highest prevalence of smoking in the home and the highest proportion of infants who had ever received vitamin supplements. The four study sites also differed significantly with respect to clinical characteristics of the infants at the first visit. A higher proportion of infants at Seeb Hospital had mild or moderate acute respiratory infections at the time of the first visit, while otitis media and diarrhea were more common among children at Nizwa Hospital.
Measles, phase I. Overall, at 9 months, 768 (87.2%) infants were seronegative, 78 (8.9%) were seropositive, and 35 (4.0%) had indeterminate results. The proportion initially seropositive ranged from 2.9% (Seeb Health Center) to 12.6% (Royal Hospital) ( ). At 7 days after the 9-month measles vaccination, P ! .01 9.9% overall were IgG seropositive, ranging from 7.5% (Nizwa) to 14.1% (Royal) ( ). The median number of days be-P p .02 tween measles vaccination at 9 months and the initial blood draw scheduled for 7 days later was 7 (range, 6-22 days); 95% of the infants were seen 6-10 days after the 9-month measles vaccination. At 30 days after measles vaccination, there were no statistically significant differences between the study sites; overall 97.6% of the children were seropositive, ranging from 97.0% (Royal) to 98.9% (Seeb). The median number of days between the 9-month vaccination and the 30-day follow-up visit was 31 (range, 28-45 days).
At 9 months, 768 infants were seronegative for measles. At the visit 7 days later, 58 (7.6%) had seroconverted, ranging from 5.1% at Nizwa to 10.8% at Royal. At the visit 30 days later, 753 (98.1%) had seroconverted, ranging from 97.3% at Ibra to 98.8% at Seeb. Of the 78 infants seropositive for measles at 9 months, 77 (98.7%) were seropositive at the visit 30 days later. At the 9-month visit, 318 infants were 8 months of age, 537 were 9 months of age, 23 were 10 months of age, and 3 Demographic and clinical characteristics, by study site, for 881 9-month-old infants at were 11 months of age. We examined seroconversion rates by age at the 9-month visit for each study site (table 2) . Overall, at the visit 7 days later, seroconversion was 6.3% among infants 8 months old, 8.5% among infants 9 months old, and 4% among infants 10-11 months old. At the visit 30 days later, seroconversion ranged from 97.2% among those 9-10 months old to 100% among those 10-11 months old. Measles, phase II. At 15 months, 47 (5.3%) of the 881 children were seronegative, ranging from 2.8% at Ibra to 6.7% at Nizwa. At 16 months, 98.8% were seropositive, ranging from 98.3% at Seeb to 99.2% at Ibra. The median number of days between the 15-and 16-month visits was 31 (range, 22-62 days). Of the 47 children who were seronegative at the 15-month visit, 44 (93.6%) were seropositive at the 16-month visit, ranging from 85.7% at Ibra to 100% at Seeb (table 3) . Fortyone (87.2%) of the 47 children seronegative at 15 months had been seropositive at the 10-month visit. Of the 78 infants seropositive at the initial 9-month visit, 69 (88.5%) were seropositive at the 15-month visit and 76 (97.4%) were seropositive at the 16-month visit.
Rubella. At age 15 months, 197 (22.4%) of the 881 children were rubella IgG positive, while 684 (77.6%) children were seronegative for rubella, ranging from 72.0% at Seeb to 81.4% at Royal. At 16 months, 8 (0.9%) were seronegative, ranging from 0.8% at Ibra and Nizwa to 1.1% at Seeb. Of the 684 children seronegative for rubella at 15 months, 676 (98.8%) were seropositive at the 16-month visit, ranging from 98.4% at Seeb to 99.0% at Ibra and Nizwa (table 3) .
Measles and rubella surveillance during the study period.
During the course of this vaccine trial, there were simultaneous outbreaks of measles and rubella. For each of these outbreaks, a subset of cases was serologically confirmed every few months by IgM ELISA testing. The measles outbreak began in the first quarter of 1992 and continued through all quarters of 1993. Altogether, 1834 measles cases were reported in 1992 (attack rate, 108/100,000 population) and 3114 cases were reported in 1993 (attack rate, 183/100,000 population) (figure 1). The rubella outbreak began in the second quarter of 1992 in Muscat and spread throughout the country (figure 2). Altogether, 211 rubella cases were reported in 1992 and 1253 rubella cases were reported in 1993. Due to the rubella outbreak, 60 infants were born with CRS [10] . All four study sites were affected by both epidemics.
Between the ages of 10 and 19 months, 14 children developed febrile rash illnesses. Of these, 13 developed the illness у30 days after receipt of the first dose of measles vaccine and before the dose of MR vaccine at 15 months. The remaining child developed the illness 66 days after MR vaccine at 15 months, and thus the cause of the illness was unknown. Of the 13 who developed febrile rash illness between the measles and MR vaccinations, 6 (46.0%) were positive for rubella IgG at 15 months of age (prior to receipt of a dose of rubella vaccine), suggesting natural rubella infection. One infant who was seronegative for measles at 10 months was measles IgG seropositive at age 15 months, which was suggestive of measles virus infection. For 10-11 0 0 0 the remaining 6 infants, the cause of febrile rash illness was not identified.
DISCUSSION
Our study confirmed the excellent immunogenicity of both measles and rubella vaccines in a developing country setting. Unlike several previous studies that reported lower measles vaccine immunogenicity (∼85%) in developing countries [11] [12] [13] [14] , we found high seroconversion rates consistently in four different areas of Oman. Although these rates were higher than expected on the basis of other studies [15] [16] [17] [18] , several studies using Schwarz measles vaccine at 9 months of age have shown high seroconversion at different time intervals after vaccination. One recent study showed high seroconversion (98.8%) 30 days after measles vaccination in 9-month-old Indonesian infants [19] ; similarly, rates of seroconversion among 400 children in Cô te d'Ivoire receiving Schwarz vaccine at 9 months were 98.1% 5 weeks after vaccination [20] . Another study in Ghana found that 98.2% of infants were IgG positive 3 months after receipt of a single dose of measles vaccine at age 9 months [21] . In Gambian infants, seroconversion was 95.2% 5 months after vaccination at age 9 months [22] . Several factors may explain the high seroconversion to measles vaccine at 9 months in our study. This study paid strict attention to cold chain maintenance and monitoring, which probably contributed to better seroconversion. It is also important to note that the vaccines in this study were administered intramuscularly. While data are limited, intramuscular administration of measles vaccine appears to be as effective as the more usual subcutaneous route [23] . Despite an ongoing outbreak of measles, a high proportion of children were measles IgG negative at age 9 months, a finding similar to that in a number of other studies of infants in developing countries [24] [25] [26] [27] . Reasons for the high percentage of seronegative children at 9 months are not clear, though it is possible that these infants had lost maternal antibodies relatively earlier than expected [28] . Reduced maternal antibody interference with the vaccine is consistent with high seroconversion rates. Seroconversion 7 days after measles vaccine at 9 months in 58 (8%; 95% confidence interval [CI], 5.8%-9.7%) of 768 of the study infants can be compared with results in a study by Helfand et al. [29] , who found 0 (95% CI, 0%-7%) of 52 Ethiopian infants IgG positive 7 days after measles vaccination at 9 months [29] , and the results likely reflect two things. First, some misclassification is expected because the specificity of this assay is not 100%, and some of these seroconversions may reflect this variability. Of 58 initially seronegative infants who were seropositive 7 days after vaccination at 9 months, 3 (5.2%) were seronegative 30 days after vaccination. Second, while every effort was made to have blood samples obtained at or as close as possible to 7 days after measles vaccination, for about half of the study infants, the 7-day blood draw was not done until after 7 days had passed. In fact, 11 of the 58 infants who appeared to have seroconverted at 7 days were actually seen from 14 to 22 days after vaccination. Comparing infants who seroconverted at 7 days to those who did not, the median number of days between vaccination and the 7-day blood draw was 7 days for each group, but the upper limit for the range was higher in the seroconverting group (22 vs. 13 days). This probably elevated the observed seroconversion rate 7 days after the 9-month vaccination. However, even after excluding infants seen у8 days after vaccination, seroconversion at the first follow-up visit was still 5.2%. The impact of the ongoing rubella outbreak was notable, as 22% of the children were rubella IgG positive at 15 months of age, an age when maternal antibody would have waned completely [30, 31] . Among seronegative children, seroconversion for rubella IgG antibody after a single dose of MR vaccine at age 15 months was high. Our finding confirms the results reported in other studies of children aged 10-24 months [32, 33] . In Brazil, Forleo-Neto et al. [16] demonstrated 100% seroconversion ∼6 weeks after a single dose of trivalent measlesmumps-rubella (MMR) vaccine in 15-month-old children. In India, Singh et al. [34] found that rubella IgG seroconversion occurred in 94% of children given a dose of MMR vaccine at age 12 or 15 months. In Brazil, De Azevedo Neto et al. [35] demonstrated 100% rubella IgG seroconversion in children who received a single dose of rubella vaccine at age 10-24 months.
A limitation of our study is the lack of follow-up blood testing to determine whether the measles antibody boosts observed after measles vaccination were prolonged or transient, particularly after two vaccine doses. However, of the 753 infants who seroconverted to measles at 30 days after vaccination at age 9 months, 726 (96.4%) were still seropositive 6 months after vaccination (i.e., at 15 months). The measles outbreak that occurred in the interim complicates these findings because there was widespread circulation of wild measles virus in all four study sites, but these data suggest that the initially high seroconversion rates were sustained over 6 months in a large percentage of the infants who seroconverted after the first dose of measles vaccine. Another limitation is that the definition of seroconversion was based on EIA results. The EIA test can be problematic in infants, and a plaque-neutralizing assay, the reference standard for measuring measles IgG antibody, was not done for confirmation [36] . In addition, it is important to note that we restricted this analysis to infants who were brought to the clinics for all five visits. There was some drop-out between the two phases of the study, and 82 infants who had completed phase I did not return at 15 months of age. However, 9-month measles seroconversion rates were virtually identical for the 993 children who completed phase I of the study to those of the 112 who completed phase I but did not complete phase II (97.9% vs. 96.7%, respectively).
The results of this trial show that in children from four different locations in Oman, one dose of measles vaccine at 9 months of age was highly immunogenic, with 98.1% seroconversion 30 days later and with 94.5% of infants still seropositive at 15 months of age. Adding a single dose of MR vaccine at age 15 months improved measles seroconversion by 16 months of age to 99% of the initially seronegative study population. One dose of MR vaccine at 15 months was similarly highly immunogenic for rubella. Our results support the use of an immunization schedule in Oman with a single dose of measles vaccine at age 9 months followed by a dose of MR vaccine at 15 months.
Follow-up status report. Because Oman implemented a 15-month dose of MR vaccine shortly after this study was completed, there are now data to assess the results of this change in immunization schedule. During March and April 1994, individuals aged 15 months to 18 years received MR vaccine in a nationwide mass campaign; 700,000 persons were vaccinated and coverage of 93% was achieved. In September 1994, a routine dose of MR vaccine was introduced for all children at 15 months of age. In 1997, MR vaccine was changed to MMR vaccine. Coverage with the 9-and the 15-month doses of measles vaccine has been у97% since 1994. In 1995, Oman joined the other countries of the Arabian Gulf in establishing a target of measles elimination by the year 2000. Also in 1995, measles surveillance was enhanced by shifting to serologic confirmation for all cases of febrile rash illness. Since then, serum specimens have been collected from 190% of individuals with febrile rash illnesses, and these are screened by IgM tests for measles and rubella (table 4) . In 2000, Oman established a rubella elimination target for the year 2005.
With respect to measles elimination, results in Oman have been striking, with the number of confirmed cases dropping to 12 in 1997, 5 in 1998, 9 in 1999, and 12 in 2000. Oman has served as a role model for the region [37] . In 1998, the 23 countries/areas of the World Health Organization (WHO) Eastern Mediterranean Region resolved to eliminate measles from One model, based on the assumption of 85% vaccine efficacy with one dose and 95% vaccine efficacy with two doses, suggests that in 2000, р3% of each age cohort !5 years of age in Oman remained susceptible to measles [38] . However, the results of the clinical trial reported in this paper suggest that the number of individuals in Oman who remain susceptible to measles may be even smaller than the numbers predicted by the model.
Global implications. Interest in a two-dose measles vaccine schedule increased worldwide during the 1990s, especially as some countries contemplated the possibility of targeting measles elimination and several regions established measles elimination targets [39] . Two papers published in 1993 reviewed the importance of two-dose measles schedules for developing countries [40, 41] . In 1993, Rosenthal and Clements [40] identified 27 countries that were using a routine immunization schedule with more than one dose of measles vaccine. By July 2001, data reported officially to WHO indicated that almost 100 countries were using a routine two-dose measles immunization schedule [42] . Moreover, the two-dose measles schedule described in this study, with the initial dose at 9 months and the second dose at 15 months, is now being used in a number of countries/territories, including Brazil, Iran, Iraq, Oman, Panama, Qatar, Republic of Korea, United Arab Emirates, West Bank and Gaza. In 2001, the WHO strategic plan of action for global measles mortality reduction and regional elimination recommended a policy of a second opportunity for measles vaccination [43] .
